Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

VMD vs DBVT vs ALKS vs PRGO vs MCK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
VMD
Viemed Healthcare, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$353M
5Y Perf.+10.6%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.-58.8%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+116.4%
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.61B
5Y Perf.-78.6%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$92.15B
5Y Perf.+374.1%

VMD vs DBVT vs ALKS vs PRGO vs MCK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
VMD logoVMD
DBVT logoDBVT
ALKS logoALKS
PRGO logoPRGO
MCK logoMCK
IndustryMedical - DevicesBiotechnologyBiotechnologyDrug Manufacturers - Specialty & GenericMedical - Distribution
Market Cap$353M$1712.35T$5.90B$1.61B$92.15B
Revenue (TTM)$287M$0.00$1.56B$4.18B$403.43B
Net Income (TTM)$15M$-168M$153M$-1.82B$4.76B
Gross Margin57.5%65.4%34.2%3.6%
Operating Margin8.2%12.3%-4.1%1.5%
Forward P/E19.2x24.8x5.6x19.3x
Total Debt$16M$22M$70M$3.97B$7.39B
Cash & Equiv.$14M$194M$1.12B$532M$5.69B

VMD vs DBVT vs ALKS vs PRGO vs MCKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

VMD
DBVT
ALKS
PRGO
MCK
StockMay 20May 26Return
Viemed Healthcare, … (VMD)100110.6+10.6%
DBV Technologies S.… (DBVT)10041.2-58.8%
Alkermes plc (ALKS)100216.4+116.4%
Perrigo Company plc (PRGO)10021.4-78.6%
McKesson Corporation (MCK)100474.1+374.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: VMD vs DBVT vs ALKS vs PRGO vs MCK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: VMD and PRGO are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Perrigo Company plc is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. DBVT, ALKS, and MCK also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
VMD
Viemed Healthcare, Inc.
The Growth Play

VMD has the current edge in this matchup, primarily because of its strength in growth exposure.

  • Rev growth 20.5%, EPS growth 32.1%, 3Y rev CAGR 24.9%
  • 20.5% revenue growth vs DBVT's -100.0%
  • 7.5% ROA vs DBVT's -89.0%
Best for: growth exposure
DBVT
DBV Technologies S.A.
The Momentum Pick

DBVT ranks third and is worth considering specifically for momentum.

  • +110.4% vs PRGO's -51.2%
Best for: momentum
ALKS
Alkermes plc
The Defensive Pick

ALKS is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
  • 9.8% margin vs PRGO's -43.5%
Best for: sleep-well-at-night
PRGO
Perrigo Company plc
The Defensive Pick

PRGO is the #2 pick in this set and the best alternative if defensive is your priority.

  • Beta 1.18, yield 9.8%, current ratio 2.76x
  • Lower P/E (5.6x vs 19.3x)
  • 9.8% yield, 10-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend)
Best for: defensive
MCK
McKesson Corporation
The Income Pick

MCK is the clearest fit if your priority is income & stability and long-term compounding.

  • Dividend streak 17 yrs, beta 0.04, yield 0.4%
  • 348.1% 10Y total return vs VMD's 413.5%
  • Beta 0.04 vs DBVT's 1.26
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthVMD logoVMD20.5% revenue growth vs DBVT's -100.0%
ValuePRGO logoPRGOLower P/E (5.6x vs 19.3x)
Quality / MarginsALKS logoALKS9.8% margin vs PRGO's -43.5%
Stability / SafetyMCK logoMCKBeta 0.04 vs DBVT's 1.26
DividendsPRGO logoPRGO9.8% yield, 10-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend)
Momentum (1Y)DBVT logoDBVT+110.4% vs PRGO's -51.2%
Efficiency (ROA)VMD logoVMD7.5% ROA vs DBVT's -89.0%

VMD vs DBVT vs ALKS vs PRGO vs MCK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

VMDViemed Healthcare, Inc.
FY 2025
Equipment Sales
66.9%$50M
Service
33.1%$25M
DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B

VMD vs DBVT vs ALKS vs PRGO vs MCK — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMCKLAGGINGDBVT

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 5 of 6 comparable metrics.

MCK and DBVT operate at a comparable scale, with $403.4B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricVMD logoVMDViemed Healthcare…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcPRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…
RevenueTrailing 12 months$287M$0$1.6B$4.2B$403.4B
EBITDAEarnings before interest/tax$46M-$112M$212M$58M$6.8B
Net IncomeAfter-tax profit$15M-$168M$153M-$1.8B$4.8B
Free Cash FlowCash after capex$26M-$151M$392M$108M$6.0B
Gross MarginGross profit ÷ Revenue+57.5%+65.4%+34.2%+3.6%
Operating MarginEBIT ÷ Revenue+8.2%+12.3%-4.1%+1.5%
Net MarginNet income ÷ Revenue+5.2%+9.8%-43.5%+1.2%
FCF MarginFCF ÷ Revenue+9.0%+25.1%+2.6%+1.5%
Rev. Growth (YoY)Latest quarter vs prior year+27.5%+28.2%-7.2%+6.0%
EPS Growth (YoY)Latest quarter vs prior year0.0%+91.5%-4.1%-56.4%+37.0%
ALKS leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

PRGO leads this category, winning 4 of 6 comparable metrics.

At 24.8x trailing earnings, ALKS trades at a 15% valuation discount to MCK's 29.2x P/E. On an enterprise value basis, VMD's 7.2x EV/EBITDA is more attractive than MCK's 18.7x.

MetricVMD logoVMDViemed Healthcare…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcPRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…
Market CapShares × price$353M$1712.35T$5.9B$1.6B$92.1B
Enterprise ValueMkt cap + debt − cash$356M$1712.35T$4.9B$5.1B$93.8B
Trailing P/EPrice ÷ TTM EPS24.89x-0.76x24.76x-1.14x29.25x
Forward P/EPrice ÷ next-FY EPS est.19.19x5.56x19.28x
PEG RatioP/E ÷ EPS growth rate0.75x
EV / EBITDAEnterprise value multiple7.21x17.25x7.42x18.74x
Price / SalesMarket cap ÷ Revenue1.31x4.00x0.38x0.26x
Price / BookPrice ÷ Book value/share2.62x0.66x3.28x0.55x
Price / FCFMarket cap ÷ FCF29.59x12.28x11.12x17.63x
PRGO leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 4 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs PRGO's 4/9, reflecting strong financial health.

MetricVMD logoVMDViemed Healthcare…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcPRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…
ROE (TTM)Return on equity+10.5%-130.2%+8.8%-50.7%+3.0%
ROA (TTM)Return on assets+7.5%-89.0%+5.4%-19.8%+5.7%
ROICReturn on invested capital+11.6%+18.9%+3.7%+5.4%
ROCEReturn on capital employed+13.2%-145.7%+14.2%+4.3%+30.5%
Piotroski ScoreFundamental quality 0–944746
Debt / EquityFinancial leverage0.11x0.13x0.04x1.35x
Net DebtTotal debt minus cash$2M-$172M-$1.0B$3.4B$1.7B
Cash & Equiv.Liquid assets$14M$194M$1.1B$532M$5.7B
Total DebtShort + long-term debt$16M$22M$70M$4.0B$7.4B
Interest CoverageEBIT ÷ Interest expense14.61x-189.82x32.30x-7.20x33.79x
MCK leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

MCK leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors MCK at 27.3% vs PRGO's -25.2% — a key indicator of consistent wealth creation.

MetricVMD logoVMDViemed Healthcare…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcPRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…
YTD ReturnYear-to-date+27.6%+4.9%+25.3%-13.5%-8.5%
1-Year ReturnPast 12 months+26.7%+110.4%+16.5%-51.2%+4.6%
3-Year ReturnCumulative with dividends-14.6%+19.7%+14.5%-58.1%+106.4%
5-Year ReturnCumulative with dividends-3.8%-69.1%+60.9%-60.1%+286.9%
10-Year ReturnCumulative with dividends+413.5%-87.0%-11.0%-77.7%+348.1%
CAGR (3Y)Annualised 3-year return-5.1%+6.2%+4.6%-25.2%+27.3%
MCK leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ALKS and MCK each lead in 1 of 2 comparable metrics.

MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricVMD logoVMDViemed Healthcare…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcPRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…
Beta (5Y)Sensitivity to S&P 5000.95x1.26x1.06x1.18x0.04x
52-Week HighHighest price in past year$10.18$26.18$36.60$28.44$999.00
52-Week LowLowest price in past year$5.93$7.53$25.17$9.23$637.00
% of 52W HighCurrent price vs 52-week peak+90.5%+76.3%+96.7%+41.2%+75.3%
RSI (14)Momentum oscillator 0–10034.748.160.260.916.2
Avg Volume (50D)Average daily shares traded312K252K2.3M3.4M757K
Evenly matched — ALKS and MCK each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — PRGO and MCK each lead in 1 of 2 comparable metrics.

Analyst consensus: VMD as "Buy", DBVT as "Buy", ALKS as "Buy", PRGO as "Hold", MCK as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 24.3% for ALKS (target: $44). For income investors, PRGO offers the higher dividend yield at 9.81% vs MCK's 0.36%.

MetricVMD logoVMDViemed Healthcare…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcPRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyHoldBuy
Price TargetConsensus 12-month target$46.33$44.00$20.00$1006.50
# AnalystsCovering analysts115283631
Dividend YieldAnnual dividend ÷ price+9.8%+0.4%
Dividend StreakConsecutive years of raises2001017
Dividend / ShareAnnual DPS$1.15$2.69
Buyback YieldShare repurchases ÷ mkt cap+3.7%0.0%+0.5%0.0%+3.4%
Evenly matched — PRGO and MCK each lead in 1 of 2 comparable metrics.
Key Takeaway

MCK leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). ALKS leads in 1 (Income & Cash Flow). 2 tied.

Best OverallMcKesson Corporation (MCK)Leads 2 of 6 categories
Loading custom metrics...

VMD vs DBVT vs ALKS vs PRGO vs MCK: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is VMD or DBVT or ALKS or PRGO or MCK a better buy right now?

For growth investors, Viemed Healthcare, Inc.

(VMD) is the stronger pick with 20. 5% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate Viemed Healthcare, Inc. (VMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — VMD or DBVT or ALKS or PRGO or MCK?

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

8x versus McKesson Corporation at 29. 2x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — VMD or DBVT or ALKS or PRGO or MCK?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: VMD returned +413. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — VMD or DBVT or ALKS or PRGO or MCK?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 2818% more volatile than MCK relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

05

Which is growing faster — VMD or DBVT or ALKS or PRGO or MCK?

By revenue growth (latest reported year), Viemed Healthcare, Inc.

(VMD) is pulling ahead at 20. 5% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Viemed Healthcare, Inc. grew EPS 32. 1% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, VMD leads at 24. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — VMD or DBVT or ALKS or PRGO or MCK?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is VMD or DBVT or ALKS or PRGO or MCK more undervalued right now?

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 19. 3x for McKesson Corporation — 13. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

08

Which pays a better dividend — VMD or DBVT or ALKS or PRGO or MCK?

In this comparison, PRGO (9.

8% yield), MCK (0. 4% yield) pay a dividend. VMD, DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.

09

Is VMD or DBVT or ALKS or PRGO or MCK better for a retirement portfolio?

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), +348. 1% 10Y return). Both have compounded well over 10 years (MCK: +348. 1%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between VMD and DBVT and ALKS and PRGO and MCK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VMD is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; MCK is a mid-cap high-growth stock. PRGO pays a dividend while VMD, DBVT, ALKS, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

VMD

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 13%
  • Net Margin > 5%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.9%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.